The avalglucosidase alfa phase 3 COMET trial in late-onset Pompe disease patients: Efficacy and safety results after 97 weeks Kishnani, P., Diaz-Manera, J., Kushlaf, H., Ladha, S., Mozaffar, T., Straub, V., Toscano, A., van der Ploeg, A. T., Berger, K. I., Clemens, P. R., Chien, Y., Day, J. W., Illarioshkin, S., Roberts, M., Attarian, S., Carvalho, G., Choi, Y., Erdem-Ozdamar, S., Goker-Alpan, O., Kostera-Pruszczyk, A., Haack, K., Thibault, N., Zhou, T., Dimachkie, M. M., Schoser, B. ACADEMIC PRESS INC ELSEVIER SCIENCE. 2022: S66-S67

View details for DOI 10.1016/j.ymgme.2021.11.168

View details for Web of Science ID 000803066100155